CA2661332A1 - Compositions et procedes pour le diagnostic et le traitement du diabete de type 2 - Google Patents

Compositions et procedes pour le diagnostic et le traitement du diabete de type 2 Download PDF

Info

Publication number
CA2661332A1
CA2661332A1 CA002661332A CA2661332A CA2661332A1 CA 2661332 A1 CA2661332 A1 CA 2661332A1 CA 002661332 A CA002661332 A CA 002661332A CA 2661332 A CA2661332 A CA 2661332A CA 2661332 A1 CA2661332 A1 CA 2661332A1
Authority
CA
Canada
Prior art keywords
diabetes
subject
type
diabetic condition
dbmarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661332A
Other languages
English (en)
Inventor
Cohava Gelber
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Type Culture Collection ATCC
Original Assignee
American Type Culture Collection
Cohava Gelber
Liping Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Type Culture Collection, Cohava Gelber, Liping Liu filed Critical American Type Culture Collection
Publication of CA2661332A1 publication Critical patent/CA2661332A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002661332A 2006-09-01 2007-03-28 Compositions et procedes pour le diagnostic et le traitement du diabete de type 2 Abandoned CA2661332A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84171706P 2006-09-01 2006-09-01
US60/841,717 2006-09-01
PCT/US2007/007875 WO2008030273A2 (fr) 2006-09-01 2007-03-28 Compositions et procédés pour le diagnostic et le traitement du diabète de type 2

Publications (1)

Publication Number Publication Date
CA2661332A1 true CA2661332A1 (fr) 2008-03-13

Family

ID=39157723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002661332A Abandoned CA2661332A1 (fr) 2006-09-01 2007-03-28 Compositions et procedes pour le diagnostic et le traitement du diabete de type 2

Country Status (6)

Country Link
EP (1) EP2069768A4 (fr)
JP (1) JP2010502946A (fr)
CN (1) CN101563597A (fr)
AU (1) AU2007293465A1 (fr)
CA (1) CA2661332A1 (fr)
WO (1) WO2008030273A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US8476008B2 (en) 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
WO2010132447A2 (fr) * 2009-05-11 2010-11-18 Diabetomics, Llc Procédés pour détecter un prédiabète et un diabète à l'aide de la glycosylation différentielle de protéines
JP5812701B2 (ja) * 2010-06-23 2015-11-17 アークレイ株式会社 血漿グルコース測定方法
WO2012000058A1 (fr) * 2010-07-02 2012-01-05 Newsouth Innovations Pty Limited Héritage d'un dysfonctionnement métabolique
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
UA119863C2 (uk) 2014-01-24 2019-08-27 Нгм Біофармасьютікалс, Інк. Антитіло або його фрагмент, що зв'язується з бета-клото
CN103969234B (zh) * 2014-04-17 2017-02-15 山东东兴汇智生物科技有限公司 一种荧光素酶‑多抗原融合蛋白以及蛋白a琼脂糖‑融合蛋白‑抗体复合物
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
SG11202005497XA (en) * 2018-02-27 2020-07-29 Agency Science Tech & Res Methods, apparatus, and computer-readable media for glycopeptide identification
CN108872293A (zh) * 2018-08-10 2018-11-23 厦门大学 一种肝泡型包虫病的代谢组学分析及初步筛查模型的构建方法
CN113539470A (zh) * 2020-04-14 2021-10-22 郑州大学第一附属医院 一种糖尿病肾病及非糖尿病性肾脏疾病鉴别诊断预测模型及构建方法
CN114404589B (zh) * 2021-12-24 2023-06-30 浙江大学 Rnase4作为治疗和/或预防糖尿病的药物靶点的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121255A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
EP1568376B1 (fr) * 2001-04-30 2012-11-21 Bayer Innovation GmbH Utilisation de l'alpha-1 antichymotrypsine pour la préparation d'une composition pour le traitement, la prévention ou le diagnostic des plaies difficilement cicatrisables associées au diabète ou aux plaies artérielles
CA2456571A1 (fr) * 2001-08-10 2003-02-20 Genset Sa Adn complementaire et proteines humains et leurs utilisations
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用
ES2398110T3 (es) * 2003-04-29 2013-03-13 Biocrine Ab ApoCIII y tratamiento y diagnóstico de la diabetes
US7648825B2 (en) * 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
JP2005337952A (ja) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc 生活習慣病予知因子
EP1615035B1 (fr) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Combinaisons de marqueurs pour détecter le diabete de type 1 et 2

Also Published As

Publication number Publication date
JP2010502946A (ja) 2010-01-28
CN101563597A (zh) 2009-10-21
AU2007293465A1 (en) 2008-03-13
EP2069768A2 (fr) 2009-06-17
EP2069768A4 (fr) 2010-01-20
WO2008030273A2 (fr) 2008-03-13
WO2008030273A3 (fr) 2008-08-28

Similar Documents

Publication Publication Date Title
CA2661332A1 (fr) Compositions et procedes pour le diagnostic et le traitement du diabete de type 2
US20080300170A1 (en) Compositions and methods for diagnosis and treatment for type 2 diabetes
US20100267052A1 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951382B2 (en) Methods for treatment of type 2 diabetes
US7951776B2 (en) Methods for treatment of type 1 diabetes
US20180106817A1 (en) Protein biomarkers and therapeutic targets for renal disorders
WO2007044860A2 (fr) Marqueurs associes au diabete et procedes d'utilisation de ceux-ci
US20100028356A1 (en) Method of diagnosing a neurodegenerative disease
CA2725599A1 (fr) Procedes de diagnostic d'un rejet d'une allogreffe de rein a l'aide d'un profilage d'expression genomique ou proteomique
US20070015183A1 (en) Biomarkers for huntington's disease
WO2019099706A1 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
JPWO2003014395A1 (ja) 気管支喘息の検査方法
EP2721175A1 (fr) Compositions et méthodes de diagnostic et de surveillance de l'hyperthyroïdie chez un félin
KR20200112906A (ko) 척추 근위축증의 치료 방법
JP2013500708A (ja) アルツハイマー病の診断のためのプロセス及び方法
US20160202273A1 (en) Biomarkers associated with diabetes and fibrosis
JP2007515155A (ja) 異なって発現される冠動脈疾患関連遺伝子
WO2018200755A1 (fr) Biomarqueurs de monocytes pour l'hypertension
EP2631656B1 (fr) Marqueur de la sclérose latérale amyotrophique, et son utilisation
JP7506606B2 (ja) 脊髄性筋萎縮症を治療する方法
CA3089120A1 (fr) Methodes de traitement de l'amyotrophie musculaire
CA2698899A1 (fr) Evaluation d'un risque d'insuffisance cardiaque congestive chez des patients traites ou pouvant etre traites avec un agoniste du recepteur gamma active par les proliferateurs des peroxysomes ou avec un thiazolidinedione

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead